Qualigen Therapeutics Inc...

NASDAQ: QLGN · Real-Time Price · USD
1.89
0.13 (7.14%)
At close: Aug 15, 2025, 3:59 PM
1.91
1.06%
After-hours: Aug 15, 2025, 06:37 PM EDT

Qualigen Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a 7.94M 9.57M 11.18M 12.57M 6.07M 5.87M 4.98M 5.07M 4.79M 4.48M 5.65M 5.28M 4.96M 4.75M
Cost of Revenue
754.29K 1.12M 1.12M 6.71M 6.97M 7.87M 8.97M 4.66M 4.74M 4.3M 4.43M 4.14M 3.96M 4.33M 5.87M 5.8M 5.69M
Gross Profit
-754.29K -1.12M -1.12M 1.23M 2.6M 3.3M 3.6M 1.41M 1.13M 680.8K 648.04K 646.95K 517.4K 1.32M -590.58K -836.28K -941.45K
Operating Income
-7.07M -5.75M -6.7M -8.21M -10.02M -12.3M -10.08M -11.69M -12.28M -13.59M -18.18M -18.61M -21.86M -22.66M -22.25M -21.16M -16.33M
Interest Income
241.75K 128.79K 48.08K n/a n/a n/a n/a 4.63K 9.46K 15.76K 15.76K 17.93K 25.83K 19.52K 29.56K 22.76K 10.04K
Pretax Income
-6.77M -6.16M -7.78M -9.22M -11.28M -13.52M -19.85M -20.68M -21.25M -21.3M -18.55M -17.36M -18.54M -17.89M -4.69M -9.94M -23.22M
Net Income
-6.87M -6.26M -7.87M -9.73M -11.62M -13.7M -19.76M -19.93M -20.59M -20.8M -18.33M -17.37M -18.54M -17.9M -4.69M -9.95M -23.22M
Selling & General & Admin
5.64M 4.2M 4.14M 4.33M 6.18M 7.04M 9.01M 10.53M 10.66M 11.79M 12.14M 12.17M 12.29M 12.27M 11.57M 11.44M 10.42M
Research & Development
865.94K 1.2M 2.55M 3.87M 4.44M 6.2M 6.67M 6.91M 7.09M 6.84M 6.68M 7.08M 10.08M 11.72M 11.94M 10.73M 6.82M
Other Expenses
557K 3.34K -351.2K -317.75K -312.07K 49.48K 44.34K 12.03K 5.97K 1.13K 2.65K 2.21K 4.94K 5.45K 3.6K 5.34K 2.99K
Operating Expenses
7.07M 5.75M 6.69M 8.2M 10.62M 13.24M 15.68M 17.45M 17.76M 18.62M 18.83M 19.25M 22.38M 23.98M 27.86M 26.52M 21.59M
Interest Expense
846K 908.94K 1.04M 1M 1.12M 1.52M 7.87M 7.51M 7.13M 6.59M n/a n/a n/a n/a n/a 715.00 58.08K
Selling & Marketing Expenses
n/a -9.74K -14.23K -14.23K 154.99K 363.84K 635.47K 875.33K 1.01M 950.42K 823.54K 713.89K 544.33K 542.59K 523.36K 491.19K 444.49K
Cost & Expenses
7.07M 5.75M 6.7M 8.21M 11.64M 15.53M 19.06M 22.1M 22.5M 22.93M 23.26M 23.39M 26.34M 28.32M 33.73M 32.32M 27.28M
Income Tax Expense
2.16K 3.91K -6.42K -4.22K -41.19K -206.75K -473.21K -703.97K -660.35K -495.84K -221.31K 10.47K 5.63K 5.43K 5.05K 6.34K 6.33K
Shares Outstanding (Basic)
1.46K 73.64 382K 7.6M 5.94M 5.22M 5.05M 5.05M 4.93M 4.21M 3.94M 3.67M 3.53M 3.13M 2.9M 2.89M 2.76M
Shares Outstanding (Diluted)
1.46K 73.64 387.88K 7.6M 5.94M 5.23M 5.05M 5.05M 4.96M 4.21M 3.94M 3.67M 3.53M 3.13M 2.9M 2.89M 2.82M
EPS (Basic)
-11.63K -11.63K -5.79 -1.74 -2.22 -2.71 -4.27 -4.52 -4.96 -5.35 -5.26 -5.27 -5.98 -6.09 -1.12 -4.24 -23.64
EPS (Diluted)
-11.63K -11.63K -5.72 -1.74 -2.22 -2.71 -4.26 -4.51 -4.95 -5.34 -5.26 -5.27 -5.98 -6.06 -1.09 -4.21 -23.61
EBITDA
-6.08M -5.25M -6.73M -8.12M -9.95M -11.67M -14.36M -15.55M -16.55M -17.86M -17.56M -18.4M -21.74M -22.63M -22.22M -25.46M -36.52M
EBIT
-5.92M -5.25M -6.73M -8.12M -10.08M -11.91M -14.08M -14.77M -15.75M -17.03M -17.27M -18.61M -21.86M -22.66M -22.25M -25.55M -36.68M
Depreciation & Amortization
1.12K 2.25K 6.74K -232.35K -110.68K 4.5K 83.08K 411.72K 380.75K 348.69K 353.01K 345.4K 331.12K 321.06K 262.03K 259.09K 264.43K